Modera Wealth Management LLC Sells 2,201 Shares of Stryker Corporation $SYK

Modera Wealth Management LLC trimmed its position in Stryker Corporation (NYSE:SYK) by 5.4% during the third quarter, HoldingsChannel.com reports. The fund owned 38,616 shares of the medical technology company’s stock after selling 2,201 shares during the quarter. Modera Wealth Management LLC’s holdings in Stryker were worth $10,635,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of SYK. Community Bank & Trust Waco Texas lifted its position in shares of Stryker by 2.3% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock worth $439,000 after buying an additional 31 shares during the last quarter. Cornerstone Financial Management LLC boosted its stake in Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares in the last quarter. NWF Advisory Services Inc. grew its position in Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after acquiring an additional 33 shares during the last quarter. Harold Davidson & Associates Inc. grew its position in Stryker by 0.4% in the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after acquiring an additional 34 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC raised its stake in Stryker by 0.9% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company’s stock worth $1,236,000 after acquiring an additional 34 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insider Activity at Stryker

In related news, insider Dylan Crotty sold 441 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock worth $118,197,701 over the last three months. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research analyst reports. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. TD Cowen dropped their price objective on shares of Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a research note on Friday. BTIG Research dropped their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating for the company in a research note on Friday. Stifel Nicolaus cut their target price on shares of Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Finally, Truist Financial decreased their target price on shares of Stryker from $340.00 to $310.00 and set a “hold” rating on the stock in a research note on Tuesday, October 6th. Sixteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $355.84.

Stryker Stock Down 6.5%

Shares of NYSE SYK opened at $291.56 on Friday. The company has a 50 day simple moving average of $292.83 and a 200 day simple moving average of $324.51. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The firm has a market cap of $111.83 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.83% and a net margin of 13.78%. The business had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. During the same period in the previous year, the firm earned $3.19 earnings per share. The company’s revenue was up 7.6% compared to the same quarter last year. On average, research analysts forecast that Stryker Corporation will post 14.93 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.